← Back to home

ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Clinical trials for ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION explained in plain language.

Never miss a new study

Get alerted when new ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION trials appear

Sign up with your email to follow new studies for ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Targeted drug trial offers hope for advanced lung cancer patients

Disease control Ongoing

This study tested whether the drug tepotinib could control advanced lung cancer in people with specific genetic changes in their tumors. Researchers enrolled 337 adults with advanced non-small cell lung cancer that had either METex14 skipping alterations or MET amplification. The…

Matched conditions: ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Get alerted when new ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION trials appear

Targeted drug trial offers hope for advanced lung cancer patients